Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-07-11
2006-07-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S153100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
07074406
ABSTRACT:
The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 4978745 (1990-12-01), Schoemaker et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6451310 (2002-09-01), Lederman et al.
patent: 6506383 (2003-01-01), Black et al.
patent: 0 555 880 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: WO 95/06480 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 98/08541 (1998-03-01), None
patent: WO 99/12566 (1999-03-01), None
Alderson et al., CD40 expression by human monocytes: regulation by citokines and activation of monocytes by the ligand for CD40, J. Exp. Med., 178:669 (1993).
Alexander-Miller, et al., Alloreactive cytotoxic Tlymphocytesgenerated in the presence of viral-derived peptides show exquisite peptide and MHC specificity, J. Immunol., 151:1-10 (1993).
Allen et al., CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome, Science, 259:990 (1993).
Andersson et al., T-cell-dependent B-cell stimulation is H2 restricted and antigen dependent only at the resting B-cell level, Proc. Natl. Acad. Sci., USA, 77:1612 (1980).
Armitage et al., Molecular and biological characterization of a murine ligand for CD40, Nature, 357:80-82 (1992).
Aruffo et al., The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome, Cell, 72:291 (1993).
Bartlett et al., Cognate interactions between helper T cells and B cells. II. Dissection of cognate help by using a class II-restricted, antigen-specific, IL-2-dependent helper T cell clone, J. Immunol., 143:1745 (1989).
Bartlett et al., Cognate interactions between helper T cells and B cells. IV. Requirements for the expression of effector phase activity by helper T cells, J. Immunol., 145:3956 (1990).
Beggington et al., High-level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker, Biol. Technology, 10:169 (1992).
Benhar et al., Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38, Proc. Natl. Acad. Sci. USA, 91:12051-12055 (1994).
Blair, P., et al., CD40 ligand (CD154) triggers a short-term CD4+ T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis, The Journal of Experimental Medicine, vol. 191, No. 4, Feb. 2000, pp. 651-660.
Brennan, et al., Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints, Eur. J. Immunol. 22: 1907-1912 (1992).
Brian, Stimulation of B-cell proliferation by membrane-associated molecules from activated T cells, Proc. Natl. Acad. Sci. USA, 85:564-568 (1988).
Bulens et al., Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer, Eur. J. Biochem., 195:235-242 (1991).
Carlsson et al., Human peripheral blood lymphocytes transplanted into SCID mice constitute anin vivoculture system exhibiting several parameters found in a normal humoral immune response and are a souce of immunocytes for the production of human monoclonal antibodies, J. Immunol., 148:1065 (1992).
Caron et al., Biological and immunological features of humanized M195 (Anti-CD33) monoclonal antibodies, Cancer Res., 32:6761-6767 (1992).
Carroll et al, Hybridoma fusion cell lines contain an aberrant kappa transcript, Mol. Immunol., 10:991 (1988.
Cathcart et al., Experimental arthritis in a non-human primate, Lab. Invest., 54:26 (1986).
Chambers-Slater, K., et al., A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation, The FASEB Journal, vol. 13, No. 5, p. 2, Mar. 15, 1999, p. A988.
Chaudary et al., A recombinant immunotoxin consisting of two antibody variable domains fused toPseudomonas exotoxin, Nature, 339:394-397 (1989).
Chu et al., Localization of tumor necrosis factor α in synovial tissue and at the cartlage-pannus function in patients with rheumatoid arthritis, Arthrit. Rheum., 39:1125 (1991).
Claman and Chaperon, Immunologic complementation between thymus and marrow cells—A model for the two-cell theory immunocompetence, Transplant Rev., 1:92-119 (1969).
Clark, CD40: A cytokine receptor in search of a ligand, Tissue Antigens 36:33 (1990).
Clement et al., Small, resting B cells can be induced to proliferate by direct signals from activated helper T cells, J. Immunol., 132:740 (1984).
Colcher et al., Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3, Cancer Res., 49:1738-1745 (1989).
Couto et al., Humanization of KC4G3, an antihuman carcinoma antibody, Hybridoma, 13(3):215-219 (1994).
Coloma, et al., Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction, J. Immunol. Meth., 152:89-104 (1992).
Courtenay et al., Immunisation against heterologous type II collagen induces arthritis in mice, Nature, 283:665 (1980).
Cox et al., A directory of human germ-line Vxsegments reveals a strong bias in their usage, Eur. J. Immunol. 24:827-836 (1994).
Crow et al., Direct T helper-B cell interactions induce an early B cell activation antigen, J. Exp. Med., 164:1760 (1986).
Crow et al., Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen, Cell Immunol., 121:99-112 (1989).
De Waele et al., Expression in non-lymphoid cells of mouse recombinant immunoglobulin directed against the tumour marker human placental alkaline phosphatase, Eur. J. Biochem., 176:287-295 (1988).
DiGiovane et al., Tumour necrosis factor in synovial exudates, Ann. Rheum. Dis., 47:68 (1988).
DiSanto et al., CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM, Nature, 361:541 (1993).
Dorai et al., The effect of dihydrofolate reductase-mediated gene amplification on the expression of transfected immunoglobulin genes, J. Immunol., 139(12):4232-4241 (1987).
Duchosal et al, The hu-PBL-SCID mouse model. Long-term human serologic evolution associated with the xeongraphic transfer of human peripheral blood leukocytes into SCID mice, Cell Immunol., 139:468 (1992).
Durie et al., Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40, Science, 261:1328 (1993).
Durie F. H. et al., Antibody to the ligand of CD40, pg39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease, J. Clin. Invest., 94:133 (1994).
Durie, et al., Antibody to the Ligand of CD40, gp39, Blocks the Occurrence of the Acute and Chronic Forms of Graft-vs-Host Disease, The American Society for Clinical Investigation, Inc., vol. 94, Sep. 1999, pp. 1333-1338.
Errata, Bio/Technol., 9:579 (1991).
Foy et al., In vivo CD-40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39, J. Exp. Med., 178:1567 (1993).
Foy et al., gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory, J. Exp. Med., 180:157 (1994).
Friedman et al., Human helper T-cell function does not require T4 antigen expression, Cell Immunol., 103:105 (1986).
Galy et al., CD40 is functionally expressed on human thymic epithelial cells, J. Immunol. 149:775-782 (1992).
Gordon et al., Resting B lymphocytes can be triggered directly through the CDw40 (Bp50) antigen, J. Immunol., 140:1425-1430 (1988).
Gruber et al., Anti-CD45 Inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation, J. Immunol., 142:4144-4152 (1989).
Grusby et al., Depletion of CD4+T cells in major histocompatibility complex class II-deficient mice, Science, 253:
Black Amelia
Hanna Nabil
Newman Roland A.
Padlan Eduardo A.
Biogen IDEC Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Treating allergic diseases with humanized anti-CD40L antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating allergic diseases with humanized anti-CD40L antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating allergic diseases with humanized anti-CD40L antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602573